Your session is about to expire
← Back to Search
Cognitive Training
Computerized Cognitive Training for Psychosis (STEP (P4) Trial)
N/A
Recruiting
Led By Sophia Vinogradov, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, immediately after the intervention, 5 month follow up
Awards & highlights
No Placebo-Only Group
Summary
This trial will examine how people with/without psychotic illness process information about their environment and if cognitive training can help.
Who is the study for?
This trial is for individuals aged 15-40 with a recent diagnosis of psychosis or related conditions, who speak English and have an IQ above 70. They must be clinically stable, not pregnant, non-dependent on substances, and without major medical or neurological issues.
What is being tested?
The study is testing two types of computerized cognitive training designed to improve information processing in young adults with psychotic illnesses compared to those without psychiatric diagnoses.
What are the potential side effects?
Since the intervention involves cognitive training exercises, side effects are minimal but may include eye strain, headache or fatigue from computer use.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, immediately after the intervention, 5 month follow up
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, immediately after the intervention, 5 month follow up
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in EEG Variables
Change in MRI Variables
Change in Performance of Bandit Task Variant
+2 moreSecondary study objectives
Change in Test My Brain Neurocognitive Assessment performance: Digit Symbol Matching Z Score
Change in Test My Brain Neurocognitive Assessment performance: Matrix Reasoning Z Score
Change in Test My Brain Neurocognitive Assessment performance: Multiracial Emotion Identification Z Score
+9 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Visual Cognitive Control TrainingExperimental Treatment1 Intervention
Training will involve maintaining accurate representations of cognitive context (the "rule") in working memory during response selection. On each training trial, participants must observe stimuli, and hold the correct response context "on-line" in order to select the correct response from among the stimuli. Training is adaptive using a staircase function, such that two consecutive correct responses increases either the speed of stimuli presentation or the working memory load via an increased number of stimuli that are presented; one incorrect response reduces the cognitive load. Each session will consist of 45 exercises requiring \~45 minutes.
Group II: Perceptual Discrimination TrainingExperimental Treatment1 Intervention
Training will involve Gabor patch and other visual stimuli discrimination exercises that focus on improving signal-to-noise resolution and attentional control with minimal working memory/cognitive control effects. On each training trial, participants are required to distinguish a target stimulus among a set of distractor stimuli. The similarity between target and distractors increases in level of difficulty based on an adaptive perceptual processing staircase function. Consecutive correct responses lead to increased modulation of the distractors to be more similar to the target, while 1 incorrect response drops the user to an easier level. Difficulty is adapted to maintain an 80% correct response rate. Each session will consist of 4 exercises requiring \~45 minutes. with 40 trials for each exercise.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computerized Cognitive Training
2019
N/A
~410
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,439 Previous Clinical Trials
1,621,758 Total Patients Enrolled
11 Trials studying Psychosis
1,425 Patients Enrolled for Psychosis
National Institute of Mental Health (NIMH)NIH
2,936 Previous Clinical Trials
2,751,441 Total Patients Enrolled
47 Trials studying Psychosis
10,593 Patients Enrolled for Psychosis
Sophia Vinogradov, MDPrincipal InvestigatorUniversity of Minnesota
13 Previous Clinical Trials
3,250 Total Patients Enrolled
8 Trials studying Psychosis
1,500 Patients Enrolled for Psychosis
Angus MacDonald III, Ph.D.Principal InvestigatorUniversity of Minnesota
1 Previous Clinical Trials
350 Total Patients Enrolled
1 Trials studying Psychosis
350 Patients Enrolled for Psychosis
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I was diagnosed with a psychosis-related disorder and am between 36-45 years old with symptoms starting in the last 5 years.I do not have, nor does my immediate family have, a history of psychotic, bipolar, or autism spectrum disorders.I have a significant neurological condition.I have been stable and out of the hospital for at least one month.I am considered capable of making decisions about joining this study.I have been stable and not hospitalized for at least a month and on a steady dose of psychiatric meds for the same time.I was diagnosed with a psychotic disorder within the last 5 years.
Research Study Groups:
This trial has the following groups:- Group 1: Perceptual Discrimination Training
- Group 2: Visual Cognitive Control Training
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.